Agilvax

Agilvax develops targeted vaccine therapies based on its proprietory virus-like particle (VLP) platform technology

Agilvax discover and develop new vaccines (including those in its current pipeline) for infectious and chronic diseases with unmet clinical need. The company identify and select lead vaccine candidates through its propietary affinity, optimizes those by in vitro and in vivo testing and develops them through pre-clinical and/or clinical testing until proof of concept is achieved establishing attractive out-licensing opportunities to Pharma or Biotech partners. Collaborations and partnerships are actively pursued within industry, academia and the government sector through NIAID.